Title: Re-evaluating the evidence for fecal microbiota transplantation "super-donors" in inflammatory bowel disease

Short title: Re-evaluating FMT "super-donors"

Authors: Scott W. Olesen, PhD[1,2]; Ylaine Gerardin, PhD[3]

1 OpenBiome, Cambridge, MA
2 Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA
3 Finch Therapeutics, Somerville, MA

Emails: solesen@openbiome.org, ylaine@finchtherapeutics.com

ABSTRACT

Fecal microbiota transplantation (FMT) is a recommended treatment for recurrent

Clostridioides difficile infection, and there is promise that FMT may be effective for

conditions like inflammatory bowel disease (IBD). Previous FMT clinical trials have

considered the possibility of a "donor effect", that is, that FMT material from different

donors has different clinical efficacies. Here we lay out rigorous statistical methodology

for detecting donor effects, finding that reliable detection of a donor effect requires trials

with more than 200 FMT-treated patients. A re-evaluation of previous FMT clinical trials

for IBD showed that while there is very little evidence for a non-zero donor effect, the

existing data are also not inconsistent with substantial donor effects. Large-scale meta-

analysis, combined with careful reporting from clinical trials, will be crucial in

determining if donor effects are clinically relevant for IBD.

INTRODUCTION

The human microbiome is increasingly understood to play a key role in health and disease.[1] Fecal microbiota transplantation (FMT), the infusion of a healthy person's stool into a patient, is one method for manipulating the gut microbiome. FMT is recommended for treatment of recurrent *Clostridioides difficile* infection.[2,3] Although the specific mechanisms by which FMT cures *C. difficile* infection are not well understood, FMT is being investigated as a therapy for dozens of other microbiome-related indications.[1]

A key challenge in identifying FMT's specific mechanism, or mechanisms, is the complexity and diversity of human stool, a mixture of bacteria, viruses, fungi, microbe-derived molecules, and host-derived molecules which varies enormously from person to person.[4,5] It has therefore been hypothesized that different stools, stool donors, or matches of donors and recipients could have different abilities to treat disease. This concept has been referred to with terms like "donor effect", "super-donor", and "super-stool".[6–9]

If FMT's efficacy varied widely across donors, then rational, *a priori* selection of stool donors based on biomarkers that predict their donated FMT material's efficacy could improve the clinical practice of FMT.[10,11] Differences in FMT efficacy between stool donors or specific stool samples could be also an important starting point for scientific investigations into the "active ingredient" in FMT donations.[6] It is therefore important to

quantify the extent of donor variability in indications where FMT is a promising

treatment.

There are no reports of a donor effect in the context of *C. difficile* infection, the condition

for which the use of FMT is best studied.[12] However, multiple studies, mostly for

ulcerative colitis, a kind of inflammatory bowel disease, have tested for donor

effects.[8,9,13–20] In all of these studies, identifying a donor effect was a *post hoc* analysis,

and in no case was multiple hypothesis correction, a critical methodology in *post hoc*

analyses, employed. As we show herein, in at least two previous reports the specifics of

the clinical design require adjustments to the statistical tests used, such that those

reports inflated the apparent evidence for a donor effect.[13,14]

Furthermore, previous reports mostly analyzed donor effects with respect to the null

hypotheses that all donors produce stool with equal clinical efficacy, or that particular

features of stool, like its bacterial community diversity, are unrelated to clinical efficacy.

We propose that, rather than merely asking if donor effects exist or not, we should ask

about the size of the donor effect, whether it is clinically relevant, and whether it is large

enough to be detected in the studies that are testing for it. It is inconceivable that all

stool has precisely the same therapeutic effect. If 2 donors are each used to treat

enough patients, the difference between their treatment efficacies would almost

certainly become statistically significant. However, without quantifying the donor effect,

it is difficult to determine if the effect is clinically relevant or to determine how many

patients would be required to power a clinical trial to reliably detect a donor effect.

Here we re-evaluate the existing evidence for donor effects and evaluate the

implications of that evidence for experimental design and clinical practice. First, we lay

out easy-to-implement but statistically rigorous methods for evaluating the donor effect

in *post hoc* analyses. Second, we use these methods to estimate the statistical power of

FMT clinical trials to detect donor effects. Finally, we apply these statistical methods to

the existing literature.

METHODS

Distinguishing types of stool superiority

Discussions of "super-donors" and "super-stool" have suggested that stool might be

superior in at least 4 distinct but conceptually related senses. To avoid confusion in our

re-evaluation of the evidence for donor effects, we distinguish between these definitions

of stool superiority:

1. *Donor superiority*, in which particular donors are associated with better clinical

outcomes for the recipient patients. For example, Moayyedi *et al.*[13] tested

whether a particular donor ("donor B") was associated with better patient

outcomes, compared to the other donors.

2. *Donor characteristic superiority*, in which a donors with some particular

characteristic are associated with better outcomes. For example, donor age, diet,

and host genetics have been suggested as potential factors in donor

superiority.[8,16,21]

3. *Donation superiority*, in which donations with some particular characteristic are
86

87   associated with better outcomes. For example, Vermeire *et al.*[22] tested whether

88   stools with higher bacterial diversity are associated with better outcomes.

4. *Donor-recipient match superiority*, in which certain combinations of donor and
89

recipient are associated with better outcomes,[8,9,20,23,24] analogous to how donors'

and recipients' blood types are matched for blood transfusions. FMT studies

have tested whether stool from "related" donors,[25] typically defined as first-

degree relatives but also sometimes including spouses or partners, is associated

with better patient outcomes.

These types of superiority are conceptually related and not mutually exclusive. For

example, imagine it were the case that female donors were associated with better

patient outcomes than male donors, making a case for "donor characteristic superiority".

However, because donors have a clinical effect on the patient only via their donation,

sex of donor cannot be the molecular mechanism by which some donations are more

efficacious than others. It would have to be that sex determined or correlated with some

component of the stool that made those donations more effective. In other words, there

must be an underlying "donation characteristic superiority" that correlates with donor

sex. Thus, even if donor-recipient match superiority might be the most accurate model,

simpler types of superiority may be parsimonious.[7]

When pools of stool from multiple donors are used for FMT, it is typical to test for donor

superiority (i.e., if the pools that include material from a particular donor are associated

with better patient outcomes)[15] and pool characteristic superiority (e.g., if pools with

higher bacterial α-diversity are associated with better patient outcomes).[17] One could

also test if particular pools are associated with better patient outcomes.

Model of donor effects and quantification of donor effect size

To quantify the size of the donor effect, we modeled each donor as having a unique

treatment efficacy, that is, the proportion of patients that would reach a positive clinical

endpoint in a very large clinical trial. The donors' treatment efficacies are drawn from a

distribution. Specifically, the log odds of the donors' treatment efficacies are normally

distributed. We used this model of distribution in donor efficacies because it

corresponds to the distribution of a random effect in a logistic regression, which can be

fit to data using well-established statistical methods.[26]

Under this model, the size of the donor effect is related to the "width" of this distribution.

If the donor effect is strong, the difference in treatment efficacies between donors tends

to be large. We defined the effect size as the median difference in treatment efficacy

between two randomly selected donors (see Supplemental Methods). For example, say

the effect size is a median difference of 10 percentage points, and the mean treatment

efficacy across donors is 50%. Then it would not be unusual if two donors selected at

random had efficacies of 45% and 55%.

Statistical power computations

We performed statistical power computations to estimate what donor effect size can be

reliably detected in an FMT clinical trial for IBD. At a range of effect sizes, statistical

power was estimated as the proportion of 1,000 simulated clinical trials with $p < 0.05$.

For each simulated clinical trial:

1. Efficacies for donors (2, 3, 6, or 12 donors) were randomly drawn from a

distribution of log odds. The mean of the distribution of log odds was selected

based on typical FMT efficacy rates (30%).[9,13,15,27] The effect size determines the

standard deviation.

2. Patients treated with FMT (12, 24, 48, 96, or 192 patients) were distributed

evenly among the donors.

3. Patients' outcomes for patients were simulated based on their donors' efficacies.

4. A statistical test (Fisher-Freeman-Halton test, see below) was run, and the p-

value noted.

If the simulated power for any effect size reached 80%, we found the effect size

corresponding to 80% power by linear interpolation.

10 effect sizes were evaluated, ranging from approximately zero (10^{-6} standard

deviation in log odds) to the difference in log odds between the typical FMT efficacy rate

and typical placebo rate for a clinical indication. This design sets the upper limit on

donor efficacies such that, at most, those donors 1 standard deviation below the mean

(i.e., ~16% of all donors) have efficacies worse than typical placebo rates (5%).

Studies re-analyzed

We analyzed a set of studies from recent FMT clinical study literature that tested for the

hypothesis that one donor or donation characteristic was associated with improved

patient outcomes (Results). To simplify the analyses, we considered only a single

dichotomous outcome, whether a patient achieved the trial's primary clinical endpoint.

We also restricted microbiome analyses to consider only the bacterial α-diversity of

stool, as associations between donor material α-diversity and patient outcomes have

been investigated in multiple studies,[14,16,22] and the hypothesis that improved bacterial

diversity in stool is part of the motivation for using pools of stool from multiple donors in

FMT.[15,23,27]

Statistical methodology

Statistics were computed using the R programming language (version 3.6.0).[28] To test

the hypothesis that there is any difference in efficacy between donors (or pools of

donors), we used the Fisher-Freeman-Halton test (function *fisher.test*) on $2 \times D$

contingency tables, where D is the number of donors (or pools). In cases when the

Fisher-Freeman-Halton test is computationally infeasible, we use the χ^2 test (function

chisq.test). For 2×2 contingency tables (e.g., to test if one donor has a different

treatment efficacy than all the others), we used Fisher's exact test (function *exact2x2*)[29]

and the mid-*p* value to prevent the tests from being overly conservative.[30] We used

logistic regressions (function *glm*) to test for donation/pool characteristic superiority. We

used random effects logistic regressions (function *glmer* from the *lme4* package)[26] to

estimate the strength of the donor effect.

Microbiome analysis

We re-analyzed raw 16S rRNA sequencing data from three studies (Kump *et al.*, study

accession PRJEB11841; Jacob *et al.*, accession PRJNA388210; Goyal *et al.*, accession

PRJNA380944) using QIIME 2[31] (version 2019.7) and Deblur.[32] Paired reads were

joined (*vsearch* plugin, default parameters), quality filtered (*quality-filter* plugin, default

parameters), and denoised using Deblur (trim length 253 nucleotides, 1 minimum reads,

otherwise default parameters). To follow Kump *et al.*'s general analysis method, each

sample in the resulting table of amplicon sequence variants was downsampled to the

minimum number of ASV counts across samples. Bacterial α-diversity was computed as

richness, the number of unique ASVs present in each sample. For Goyal *et al.*, the

sequencing data was single-ended, so reads were not paired for that study. When a

donor had multiple samples, we associated a single α-diversity with each donor by

computing the average number of ASVs over that donor's samples.

Code and data availability

Computer code and underlying data to reproduce the results are online at

https://www.github.com/openbiome/donor-effects.

RESULTS

Statistical power of FMT clinical trials for IBD to detect a donor effect

Using simulations, we estimated the minimal strength of the donor effect required for an FMT clinical trial for IBD to reach 80% statistical power in detecting a donor effect with a Fisher-Freeman-Halton test (Figure 1). Trials' ability to reliably detect a donor effect increased with the strength of the donor effect, the number of patients, and the number of donors in the trial. More patients and donors allowed for reliable detection of weaker donor effects.

For trials with 24 patients and any number of donors, the strength of the donor effect required for reliable detection of that effect was implausibly large: it would require that a substantial fraction of donors caused their patients to perform worse than placebo (see Methods). Similarly, studies with 2 donors and 192 or fewer patients were also unable to detect plausible donor effects. Trials with 96 patients were able to reliably detect a donor effect when the median difference in treatment efficacy between randomly selected donors was 20 percentage points or more. In other words, the donor effect must be strong enough that, in a typical pair of donors, one might have a clinical efficacy of 20% and the other 40%. Even with 384 patients in a trial, the donor effect would need to be large enough that the median difference in clinical efficacy between randomly selected donors was more than 10 percentage points.

Re-evaluations of the evidence for a donor effect in IBD

The results of the statistical power computations above suggest that previous studies of

FMT for IBD are unlikely to have detected a donor effect. We therefore re-evaluated the

evidence for a donor effect in IBD from a selection of FMT clinical studies (Table 1).

Rossen et al. 2015

In this study,[9] 23 ulcerative colitis patients were treated with FMT. 17 patients received

stool from 1 of 15 donors; 6 patients received stool from 2 different donors. In the

original publication, the investigators report on the performance of 3 donors (Table 2).

There was no evidence of a donor effect (mid-$p > 0.05$, Fisher's exact test) for any of

the 3 donors. However, the study is small enough that the data are not inconsistent with

large variability between donors. For example, the upper 95% confidence interval on

donor A's odds ratio of successful patient outcome compared to all other donors is 29.

In other words, the data do not provide evidence of a donor effect, but they also cannot

definitively rule out a strong donor effect.

Moayyedi et al. 2015

In this study,[13] 38 ulcerative colitis patients were treated with FMT. Each patient was

treated with stool from 1 of 6 donors. Donors were used according to an adaptive

process, described in the original publication. Briefly, at the start of the trial, patients

were treated with stool from one of two donors (A or B). Material from donor B then

became unavailable, and patients were instead treated with stool from donor A or 1 of 4

other donors (C, D, E, and F). At this point, donor B became available again, and "[t]he

remaining participants allocated to active therapy all received FMT from donor B

exclusively, as [the investigators] had not experienced any success with donor A". In the

original study, donor B's performance (7 of 18 treated patients achieved the primary

endpoint) was compared against all other donors (2 of 20 patients; odds ratio 5.5 [95%

CI 1.0 to 44], mid-p = 0.048, Fisher's exact test).

In general, adaptive trial designs require special statistical methodologies.[33] However,

we were aware of no statistical methodologies designed to account for an adaptive

design like the one used in this trial. To investigate whether typical statistical tests like

Fisher's exact test or a χ^2 test accurately measure the statistical significance of the

collected data, we simulated a simplified adaptive donor selection process. Among the

first 24 patients, use all 6 donors 4 times each. Then exclusively use the best-

performing donor for the remaining 14 patients. Finally, compare the overall

performance of this donor against all the others. In these simulations, if all the donors

are the same, the probability of finding mid-p < 0.05 is approximately 9%, greater than

that 5% that would be expected if the test were accurate for that type of data

(Supplemental Results). The intuitive explanation is that, if all donors are the same, the

selection process is merely setting aside donors who had "bad luck" on their first

patients, and they are not allowed to recover their performance with a run of "good luck"

later on. This is not a flaw of Fisher's exact test. Instead, it is problem of applying a

statistical test to data that do not meet the assumptions of the test.

Although the adaptive procedure that led to extensive use of donor B may have

improved the probability of the trial's success,[7] the procedure was not pre-specified,

making it impossible to rigorously determine the degree to which the observed results

are consistent with all donors being identical, that is, whether donor B simply had a

"lucky" initial run. Thus, the value mid-$p \approx 0.05$ reported above is inaccurately optimistic,

and a value closer to 0.09 is a better representation of the likelihood of a donor having

the kind of success observed in this trial.

Paramsothy et al. 2017

In this study,[15] 41 ulcerative colitis patients were randomized to receive FMT, and

another 37 were randomized to placebo and later received FMT. Each patient received

FMT from 1 of 21 pools of donors. Each pool included 3 to 7 donors, out of 13 total

donors.

The original publication compared the best performing individual donor against all the

others (14 of 38 patients achieved the primary outcome, versus 7 of 40 assigned to

other donors; odds ratio 2.7 [95% CI 0.96 to 8.2], mid-$p = 0.06$, Fisher's exact test). This

result, although near mid-$p = 0.05$, was not subjected to multiple hypothesis correction,

as there are 13 relevant hypotheses to be tested, one per donor. In terms of pools of

donors, there was also no evidence that any particular pool was associated with better

outcomes ($p = 0.57$, Fisher-Freeman-Halton test on 2 × 21 table of patient outcomes by

pool).

To develop an estimate of the strength of the donor effect, we used a logistic

regression, modeling the pool as a random effect. This model estimated that the median

difference between the efficacy of two randomly selected pools is 0 percentage points

(95% CI 0 to 20 percentage points). In other words, the regression's best estimate of

the variation in efficacy among pools is zero, even without applying any penalizations

for model complexity. Thus, similar to Rossen *et al.*, the data do not provide evidence

for a donor effect, but they are also not inconsistent with a strong effect, since the upper

confidence limit on the strength of the donor effect is 20 percentage points.

Costello et al. 2019

In this study,[27] 38 ulcerative colitis patients received FMT from 1 of 11 pools. Each pool

included stool from 3 or 4 donors, out of 19 total donors. Similar to Paramsothy *et al.*,

there was no evidence of heterogeneity in patient outcomes by donor pool ($p = 0.50$,

Fisher-Freeman-Halton test on 2 × 11 table) nor evidence of better outcomes for any

particular donor (mid-$p > 0.05$ for all donors, Fisher's exact test). Furthermore, a logistic

regression estimated the median difference between two randomly selected donors as 0

percentage points (95% CI 0 to 26 percentage points).

Jacob et al. 2017

In this study,[17] 20 ulcerative colitis patients received FMT from 1 of 6 pools. Each pool

included stool from 2 donors, out of 4 total donors. In this analysis, we analyzed only the

14 patients available for follow-up at 12 weeks, using remission at this timepoint as the

outcome. Similar to Paramsothy *et al.* and Costello *et al.*, there was no evidence for

differences in patient outcomes by pool (Fisher-Freeman-Halton test on 2 × 4 table, $p = $

0.86) or by donor (mid-$p > 0.05$ for all 4 donors, Fisher's exact test). A logistic

regression estimated the median difference in efficacy between two randomly selected

pools as zero (95% CI 0 to 31 percentage points).

The pools administered to 13 of the 14 patients were characterized using 16S rRNA

sequencing, allowing for an analysis of patient outcomes by bacterial characteristics of

the pools (Figure 2). However, there was no evidence for an association between

patient outcomes and the bacterial community α-diversity, measured as the number of

unique amplicon sequence variants (ASVs, i.e., denoised 100% OTUs), of the pool they

received (p = 0.18, Wilcoxon rank-sum test).

To develop confidence intervals around the strength of the donor effect, we fit a logistic

regression to the data, predicting patient outcomes from pool α-diversity. The model's

point estimates for pool efficacy was 20% (95% CI 2% to 76%) for the pool with the

lowest α-diversity (239 ASVs) but 84% (95% CI 25% to 99%) for the pool with the

highest diversity (487 ASVs). In other words, the data do not provide statistically

significant evidence for an association between pool α-diversity and patient outcomes,

but they cannot definitively rule out the possibility of a wide variation in efficacy between

pools.

Meta-analysis of pool studies

Paramsothy *et al*., Costello *et al.*, and Jacob *et al.* have sufficiently similar designs and

the available data to allow a meta-analysis. A logistic regression on the combined data

from all three studies, with the study as a fixed effect, estimated the median difference

in efficacy between two randomly selected pools as zero, with a smaller confidence

interval than for any individual study (95% CI 0 to 16 percentage points).

Goyal et al. 2018

In this study,[16] 21 patients with inflammatory bowel disease (any of Crohn's disease,

ulcerative colitis, or indeterminate colitis) received FMT and were available for follow-up.

We used remission at 30 days as the outcome. Each patient received stool from 1

donor, precluding any test of donor superiority. However, 16S rRNA sequencing was

performed, allowing for an analysis of donation characteristic superiority, similar to

Jacob *et al.* above.

Similar to that study, there was no evidence for an association between patient

outcomes and the α-diversity (p = 0.3, Wilcoxon rank-sum test), but a logistic regression

estimated a potentially wide but statistically insignificant variation in donation efficacy

across the range of α-diversities among donors, predicting an efficacy of 38% (95% CI

8% to 82%) for the donor with the lowest α-diversity (386 ASVs) and an efficacy of 75%

(95% CI 26% to 96%) for the donor with the highest diversity (1072 ASVs). Again, there

was no statistically significant association between patient outcomes and donor stool

characteristics, but the data are not inconsistent with a wide variation.

Kump et al. 2017

In this study,[14] 17 ulcerative colitis patients received FMT from 1 of 14 donors. 12

donors were used in 1 patient, 1 donor was used in 2 patients, and 1 donor was used in

3 patients. Like Jacob *et al.* and Goyal *et al.*, this study tested whether increased α-

diversity was associated with improved patient outcomes.

In the original analysis, the 4 patients who did not respond clinically to FMT were

compared against the 4 patients who reached remission (Figure 2). 16S rRNA

sequencing data was available for 28 donations associated with those 8 patients.

Donors assigned to patients who received remission did not have statistically

significantly higher α-diversity than those assigned to patients who did not respond

(Wilcoxon rank-sum test, p = 0.3).

The original publication reported statistically significant differences between the α-

diversity of stool samples associated with remission (n = 16) compared to samples

associated with no response (n = 12; p = 0.11). Our analysis has a different conclusion,

finding no support for a donor effect, principally because we analyzed the data as only 8

independent data points (i.e., one for each patient), while Kump *et al.* analyzed the data

as if there were 28 independent data points (i.e., one for each donation that was

administered to a patient that also has associated microbiome data). Repeated

measurements of the material delivered to a patient do not constitute independent

measures of the patient's outcome. In other words, when testing for an association

between patient outcomes and a donation characteristic like α-diversity, the weight of

the evidence is determined by the number of patient outcomes, not by the number of

microbiome measurements.

As an extreme example, consider a study with two donors and two patients: donor A is

used with a patient who achieves remission, while donor B is used with a patient who

has no response to FMT. If 100 microbiome samples were taken from each of donors A

and B, a difference between A's and B's samples could be found with great statistical

confidence. However, this does not translate into confidence in the relationship between

the microbiome and patient outcome.

Similar to the studies above, a logistic regression identified a potentially wide but not

statistically significant variation in donation efficacy across the range of α-diversities,

predicting an efficacy of 38% (95% CI 8% to 82%) for the donor with the lowest α-

diversity (386 ASVs) and an efficacy of 75% (95% CI 26% to 96%) for the donor with

the highest diversity (1072 ASVs).

Vermeire et al. 2016

In this study, 14 patients with inflammatory bowel disease (either of Crohn's disease or

ulcerative colitis) received FMT, each from a different donor. The original study reported

that the bacterial α-diversity of donations varied by patient outcomes, that patients with

successful outcomes received more bacterially diverse donations (Wilcoxon rank-sum

test, p = 0.012). However, the underlying bacterial sequencing data was not available

for re-analysis.

Nishida et al. 2017

In this study, 41 patients with ulcerative colitis received FMT, each from a different

donor. The original study found no difference in the α-diversity of the stool from 7

donors whose patients met the primary endpoint, compared to 19 donors whose

patients did not ($p = 0.69$). The study also tested whether the abundance of 10 taxa

were differentially abundant among those two groups of donors, finding p-values less

than 0.05 for 2 of 9 taxa, neither of which was significant after Benjamini-Hochberg

multiple hypothesis correction.[34] The underlying bacterial sequencing data was not

available for re-analysis.

DISCUSSION

In simulation of FMT clinical trials for IBD, we found that trials would need to be very

large, with more than 200 patients receiving FMT, to achieve 80% statistical power to

detect a modest donor effect (median 10 percentage point difference in efficacy

between two randomly selected donors). In other words, if the donor effect were only

strong enough that randomly selected pairs of donors had a 10 percentage point

difference in efficacy —say, one having a 30% efficacy and the other a 40% efficacy—

then no existing trial of FMT for IBD had a design that could reliably detect such an

effect.

Concluding that existing FMT studies for IBD were simply not powered to detect donor

effects, we re-evaluated reports from those studies, finding no statistically rigorous

evidence for the superiority of particular donors and only very weak evidence for

variation in FMT's efficacy based on the α-diversity of the FMT material (specifically, a

single result from Vermeire *et al.*). In most cases, the statistical best estimate for the

strength of the donor effect is exactly zero. However, the small size of these studies

relative to the number of patients required to reliably detect a plausible donor effect also

means that the data cannot definitively rule out a large donor effect, as much as 20 or

30 percentage points between randomly selected donors. It therefore remains

undetermined if differences between donors are clinically relevant to FMT for IBD.

These sobering results are subject to multiple limitations. First, we measured the

associations between very simple measures. We considered only dichotomous patient

outcomes and the relatively simple microbiological characteristic of bacterial α-diversity

as determined by 16S rRNA taxonomic marker gene sequencing. Reliably detecting

donor effects may require more sophisticated methods. For example, Jacob *et al.* report

that donors' bacterial compositions meaningfully differed with respect to patient

outcomes (Figure 4C in that publication, PERMANOVA, $p = 0.044$). More proximal and

fine-grained measurements of patients' response to FMT may also provide more

sensitivity for detecting differences in donor efficacies. Dichotomous primary endpoints

and ordinal changes in patients' Mayo scores are subject to enormous sources of

variance in the patient's biology and disease history that may be hiding the more subtle

effects of differences between donors.

Second, we modeled the distribution of donors and pool efficacies as Gaussian in log

odds space. This approach allowed us to use mixed model logistic regression, a well-

established statistical procedure, to estimate the variance in donors' efficacies, but it is

not an intuitive measure of variation. Furthermore, this model of donor variability does

not require that all donors' efficacies be higher than the placebo rate. A model of donor

variability that does sensibly account for placebo rates was previously used in a study of

FMT clinical trial design,[7] but that model would require adaptation to make it suitable for

statistical inference.

In light of the number of patients required for a well-powered test for a donor effect, we

propose that an important path is meta-analysis across clinical trials, compiling

characterizations of donors' and patients' microbiomes and host factors, linked with

patient outcomes.[6] This approach will present difficult technical challenges, as data from

multiple studies be carefully collected, cleaned, and analyzed to make the analytical

results valid across those studies.[35] However, liberal sharing of clinical metadata and

microbiome data, including careful reporting of donor and donation characteristics, will

more easily enable inference across studies, and may provide the best direction forward

to characterizing the donor effect for FMT in IBD.

Author contributions

SWO conceived the study, obtained data, performed the analysis, and wrote the

manuscript. YG obtained data; improved the analysis, interpretation, and presentation of

the results; and revised the manuscript.

Acknowledgements

REFERENCES

1. Marchesi, J. R. *et al.* The gut microbiota and host health: a new clinical frontier. *Gut*

65, 330–339 (2016).

2. McDonald, L. C. *et al.* Clinical Practice Guidelines for Clostridium difficile Infection in

Adults and Children: 2017 Update by the Infectious Diseases Society of America

(IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin. Infect. Dis.*

66, e1–e48 (2018).

3. Debast, S. B., Bauer, M. P. & Kuijper, E. J. European Society of Clinical Microbiology

and Infectious Diseases: Update of the Treatment Guidance Document for

Clostridium difficile Infection. *Clin. Microbiol. Infect.* **20**, 1–26 (2014).

4. David, L. A. *et al.* Diet rapidly and reproducibly alters the human gut microbiome.

Nature **505**, 559–563 (2014).

5. The Human Microbiome Project Consortium. Structure, function and diversity of the

healthy human microbiome. *Nature* **486**, 207–214 (2012).

6. Olesen, S. W., Leier, M. M., Alm, E. J. & Kahn, S. A. Searching for superstool:

maximizing the therapeutic potential of FMT. *Nat. Rev. Gastroenterol. Hepatol.* **15**,

387–388 (2018).

7. Olesen, S. W., Gurry, T. & Alm, E. J. Designing fecal microbiota transplant trials that

account for differences in donor stool efficacy. *Stat. Methods Med. Res.* **27**, 2906–

2917 (2018).

8. Wilson, B. C., Vatanen, T., Cutfield, W. S. & O'Sullivan, J. M. The Super-Donor

Phenomenon in Fecal Microbiota Transplantation. *Front. Cell. Infect. Microbiol.* **9**, 2

(2019).

9. Rossen, N. G. *et al.* Findings From a Randomized Controlled Trial of Fecal

Transplantation for Patients With Ulcerative Colitis. *Gastroenterology* **149**, 110-

118.e4 (2015).

10.   Barnes, D. *et al.* Competitively Selected Donor Fecal Microbiota Transplantation:

Butyrate Concentration and Diversity as Measures of Donor Quality. *J. Pediatr.*

Gastroenterol. Nutr. **67**, 185–187 (2018).

11.   Duvallet, C. *et al.* Framework for rational donor selection in fecal microbiota

transplant clinical trials. *medRxiv* (2019) doi:10.1101/19000307.

12.   Osman, M., Abend, A., Panchal, P., Kassam, Z. & Budree, S. 88 - Does the

Donor Matter? Microbiome Sequencing to Evaluate Lower Donor Efficacy in Fecal

Microbiota Transplantation for Recurrent Clostridium Difficile Infection.

Gastroenterology **154**, S-25-S-26 (2018).

13.   Moayyedi, P. *et al.* Fecal Microbiota Transplantation Induces Remission in

Patients With Active Ulcerative Colitis in a Randomized Controlled Trial.

Gastroenterology **149**, 102-109.e6 (2015).

14.   Kump, P. *et al.* The taxonomic composition of the donor intestinal microbiota is a

major factor influencing the efficacy of faecal microbiota transplantation in therapy

refractory ulcerative colitis. *Aliment. Pharmacol. Ther.* **47**, 67–77 (2018).

15.   Paramsothy, S. *et al.* Multidonor intensive faecal microbiota transplantation for

active ulcerative colitis: a randomised placebo-controlled trial. *Lancet Lond. Engl.*

389, 1218–1228 (2017).

16.   Goyal, A. *et al.* Safety, Clinical Response, and Microbiome Findings Following

Fecal Microbiota Transplant in Children With Inflammatory Bowel Disease. *Inflamm.*

Bowel Dis. **24**, 410–421 (2018).

17.   Jacob, V. *et al.* Single Delivery of High-Diversity Fecal Microbiota Preparation by

Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active

Ulcerative Colitis: *Inflamm. Bowel Dis.* **23**, 903–911 (2017).

18.   Allegretti, J. R., Mullish, B. H., Kelly, C. & Fischer, M. The evolution of the use of

faecal microbiota transplantation and emerging therapeutic indications. *Lancet Lond.*

Engl. **394**, 420–431 (2019).

19.   Nishida, A. *et al.* Efficacy and safety of single fecal microbiota transplantation for

Japanese patients with mild to moderately active ulcerative colitis. *J. Gastroenterol.*

52, 476–482 (2017).

20.   Paramsothy, S. *et al.* Faecal Microbiota Transplantation for Inflammatory Bowel

Disease: A Systematic Review and Meta-analysis. *J. Crohns Colitis* **11**, 1180–1199

(2017).

21.   Budree, S. *et al.* The Association of Stool Donor Diet on Microbial Profile and

Clinical Outcomes of Fecal Microbiota Transplantation in Clostridium Difficile

Infection. *Gastroenterology* **152**, S630–S631 (2017).

22.   Vermeire, S. *et al.* Donor Species Richness Determines Faecal Microbiota

Transplantation Success in Inflammatory Bowel Disease. *J. Crohns Colitis* **10**, 387–

394 (2016).

23.   Kazerouni, A. & Wein, L. M. Exploring the Efficacy of Pooled Stools in Fecal

Microbiota Transplantation for Microbiota-Associated Chronic Diseases. *PloS One*

12, e0163956 (2017).

24.   Davido, B. *et al.* Impact of Fecal Microbiota Transplantation for Decolonization of

Multidrug-Resistant Organisms May Vary According to Donor Microbiota. *Clin. Infect.*

Dis. (2017) doi:10.1093/cid/cix963.

25.   Khanna, S. *et al.* Changes in microbial ecology after fecal microbiota

transplantation for recurrent C. difficile infection affected by underlying inflammatory

bowel disease. *Microbiome* **5**, (2017).

26.   Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting Linear Mixed-Effects

Models Using **lme4**. *J. Stat. Softw.* **67**, (2015).

27.   Costello, S. P. *et al.* Effect of Fecal Microbiota Transplantation on 8-Week

Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. *JAMA*

321, 156–164 (2019).

28.   R Core Team. *R: a language and environment for statistical computing.* (R

Foundation for Statistical Computing, 2019).

29.   Fay, M. P. Confidence intervals that match Fisher's exact or Blaker's exact tests.

Biostatistics **11**, 373–374 (2010).

30.   Mehta, C. R. & Hilton, J. F. Exact Power of Conditional and Unconditional Tests:

Going beyond the 2 × 2 Contingency Table. *Am. Stat.* **47**, 91–98 (1993).

31. Bolyen, E. *et al.* Reproducible, interactive, scalable and extensible microbiome

data science using QIIME 2. *Nat. Biotechnol.* **37**, 852–857 (2019).

32. Amir, A. *et al.* Deblur Rapidly Resolves Single-Nucleotide Community Sequence

Patterns. *mSystems* **2**, (2017).

33. Bhatt, D. L. & Mehta, C. Adaptive Designs for Clinical Trials. *N. Engl. J. Med.*

375, 65–74 (2016).

34. Yekutieli, D. & Benjamini, Y. The control of the false discovery rate in multiple

testing under dependency. *Ann. Stat.* **29**, 1165–1188 (2001).

35. Gibbons, S. M., Duvallet, C. & Alm, E. J. Correcting for batch effects in case-

control microbiome studies. *PLoS Comput. Biol.* **14**, e1006102 (2018).

FIGURES AND TABLES

Figure 1: Statistical power calculations showing detectable effect sizes for varying trial

designs. In simulated clinical trials, a number of patients (vertical axis) are evenly

allotted to a number of donors (horizontal axis). Each tile's color and number show the

minimum effect size (median difference in efficacy, measured in percentage points,

between two randomly selected donors) required for the trial design to reach 80%

statistical power. Gray tiles show that 80% statistical power cannot be achieved for

plausible donor variations (i.e., for which most donors perform at least as well as

placebo). p.p.: percentage points.

Table 1: Summary of re-analyses.

Data source	Indication	No. patients	No. donors	No. pools	Evidence for donor superiority?	Evidence for pool superiority?	Association between diversity and outcomes?
Rossen *et al.*	IBD	23	15	—	No	—	—
Moayyedi *et al.*	IBD	38	6	—	No*	—	—
Paramsothy *et al.*	IBD	78	13	21	No	No (0 p.p., 95% CI 0 to 20)†	—
Costello *et al.*	IBD	38	19	11	No	No (0 p.p., 95% CI 0 to 26)	—
Jacob *et al.*	IBD	21	4	6	No	No (0 p.p., 95% CI 0 to 31)	No
Pool meta-analysis‡	IBD	137	36	38	No	No (0 p.p., 95% CI 0 to 16)	—
Goyal *et al.*	IBD	21	21	—	—	—	No
Kump *et al.*	IBD	17	14	—	—	—	No
Vermeire *et al.*	IBD	14	14	—	—	—	Reported§
Nishida *et al.*	IBD	41‖	41‖	—	—	—	No

p.p.: Percentage points
*: See Results regarding the difficulty in matching statistical methods with the experimental design.
†: Median difference in clinical efficacy between two randomly selected pools.
‡: Includes data from Paramsothy *et al.*, Costello *et al.*, and Jacob *et al.* Numbers of patients, donors, and pools are the sum of the values from
those studies.
‖: Underlying data not available for re-analysis. Original publication reports that 14 patients were analyzed, but the figure (3a in Vermeire *et al.* only
reports data from 13.
§: Only 13 of 14 patients were analyzed for a donor effect.
601

602 **Table 2**: Tests of donor superiority, by donor, for Rossen *et al.* Donor labels are

603 arbitrary. "Success" means the patient reached the primary endpoint; "failure" means

604 they did not.

	Patients treated using this donor		Patients treated not using this donor			
Donor	Success	Fail	Success	Fail	Odds ratio (95% CI)	Mid-*p* (Fisher's exact test)
A	4	4	3	12	3.7 (0.43 to 39)	0.18
B	1	2	6	14	1.2 (0.02 to 27)	0.89
C	0	2	7	14	0.0 (0.0 to 13)	0.47

Figure 2: Bacterial α-diversity of FMT pools (vertical axis) do not significantly differ by

patient outcomes (columns), in Jacob *et al.* (p = 0.18, Wilcoxon rank-sum test). Each

point represents a single patient. The diversity shown for each patient (vertical axis) is

the average of the number of unique 16S rRNA amplicon sequence variants (ASVs) in

the sampled FMTs that were used in that patient.

Figure 3: Bacterial α-diversity do not differ by patient outcome in re-analysis of Kump *et*

al.'s data when the unit of analysis is the patient (Wilcoxon test, $p > 0.05$ for all 3

comparisons). Each point represents a single patient. The diversity shown for each

patient (vertical axis) is the average of the diversity of the sampled FMTs used in that

patient.

SUPPLEMENTAL METHODS

Calculating the median difference in treatment efficacy between two randomly

selected donors

To convert a mean and standard deviation, measured in terms of log odds ratios, into

the median difference in treatment efficacy between two randomly selected donors,

measured in terms of percentage points:

1. 2 million random variates are drawn from a normal distribution with that mean log

   odds and standard deviation

2. These values are transformed into probabilities

3. The difference between subsequent values is calculated, and the median

   determined

SUPPLEMENTAL RESULTS

Moayyedi *et al.* adaptive simulation

To determine this probability, we simulated 10,000 clinical trials. In each trial:

- 6 donors had 4 success/fail trials with probability of success 9 / 39 = 0.23.
- The best performing donor (or, in the case of a tie, a randomly selected donor

  among the best performers) had 14 additional success/fail trials with the same

  probability of success

643   •   The performance of the donor with 18 patients was compared against the

644   aggregate performance of the other donors, with 20 patients, using a Fisher's

645   exact test.

647   The test returned mid-$p < 0.05$ in 8.6% of simulations ($n = 866$; 95% CI 8.1% to 9.2%).